A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep

Yu, Wei; Zhu, Jian; Wang, Yitian; Wang, Junjie; Fang, Weijing; Xia, Kaishun; Shao, Jianlin; Wu, Min-Zu; Liu, Bing; Liang, Chengzhen; Ye, Chengyi; Tao, Huimin

doi:10.18632/oncotarget.16243

Cited by 46 publications

(35 citation statements)

References 144 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Osteosarcoma (OS) is a type of malignant tumor commonly presenting in children, and adolescents (1) under 20 years of age (2). OS is caused by pathological changes in mesenchymal tissue in the bone, especially in the metaphysis of long bones (3).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

Xie

Zuo

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are integrally involved in biological and pathobiological development. Many studies have demonstrated the abnormal expression of microRNA-496 (miR-496) in various human malignant tumors. The present study was designed to investigate the functions and the underlying mechanisms of miR-496 in osteosarcoma (OS) progression. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression of miR-496 in OS tissues and cell lines. Luciferase activity was used to confirm the interaction between miR-496 and brain derived neurotrophic factor (BDNF), a downstream gene of miR-496. RT-qPCR was also used to quantify BDNF mRNA expression, and the BDNF protein expression level was detected by western blot analysis. In addition, the Cell Counting Kit-8 (CCK-8) was used to detect cell viability. The results revealed that the level of miR-496 expression was significantly reduced in osteosarcoma tissues and cell lines. BDNF was verified to be a direct target gene of miR-496 and was found to be negatively regulated by miR-496. Overall, it was demonstrated that miR-496 inhibits osteosarcoma cell proliferation via inhibition of BDNF. Thus, the miR-496/BDNF axis may be a novel strategy for the clinical treatment of OS.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

Xie

Zuo

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…The addition of Mifamurtide (MTP-PE) has been shown to improve the overall survival rate [ 13 , 14 ]. However, the search for novel targeted therapies to improve outcomes for patients with OS remains an area of active research including immunotherapy [ 15 , 16 , 17 ], photodynamic therapy [ 18 ], treatment with nanoparticles [ 19 , 20 ], and the combination of CAP and iron nanoparticles [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Cold Atmospheric Plasma in the Treatment of Osteosarcoma

Gümbel

Bekeschus

Gelbrich

et al. 2017

IJMS

View full text Add to dashboard Cite

Human osteosarcoma (OS) is the most common primary malignant bone tumor occurring most commonly in adolescents and young adults. Major improvements in disease-free survival have been achieved by implementing a combination therapy consisting of radical surgical resection of the tumor and systemic multi-agent chemotherapy. However, long-term survival remains poor, so novel targeted therapies to improve outcomes for patients with osteosarcoma remains an area of active research. This includes immunotherapy, photodynamic therapy, or treatment with nanoparticles. Cold atmospheric plasma (CAP), a highly reactive (partially) ionized physical state, has been shown to inherit a significant anticancer capacity, leading to a new field in medicine called “plasma oncology.” The current article summarizes the potential of CAP in the treatment of human OS and reviews the underlying molecular mode of action.

show abstract

“…Conclusion: Our data identify the role of miR-20a in osteosarcoma growth, indicating its potential application in chemotherapy. Osteosarcoma is the most common primary malignant bone tumor with high morbidity in young adults and children, comprising 2.4% of all malignancies in pediatric patients and about 20% of all primary bone tumors [1]. It occurs mainly around regions with active bone growth and reparation.…”

mentioning

confidence: 99%

MiRNA-20A Upregulates TAK1 and Increases Proliferation in Osteosarcoma Cells

Yuan

Zhao

et al. 2018

Future Oncol.

View full text Add to dashboard Cite

Aim:The aim of this study is to explore the function of miR-20a in osteosarcoma. Materials & methods: miR-20a expression was measured by real-time PCR. miR-20a mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on colony formation and tumor growth. Moreover, relationships of miR-20a with TAK1 were investigated by western blot and luciferase activity. Results: We found that miR-20a was downregulated in osteosarcoma, and overexpression of miR-20a reduced colony formation and tumor growth. Furthermore, the data revealed that the function of miR-20a was probably exerted via targeting the TAK1 expression. Overexpression of miR-20a sensitizes the osteosarcoma cells to chemotherapeutic drugs. Conclusion: Our data identify the role of miR-20a in osteosarcoma growth, indicating its potential application in chemotherapy. Osteosarcoma is the most common primary malignant bone tumor with high morbidity in young adults and children, comprising 2.4% of all malignancies in pediatric patients and about 20% of all primary bone tumors [1]. It occurs mainly around regions with active bone growth and reparation. Osteosarcoma is highly aggressive and responded poorly to chemotherapy, and the 5-year survival rate for patients with metastatic osteosarcoma is only 14% [2]. Therefore, it is of extreme significance to elucidate novel molecular targets to develop alternative therapeutic target for this disease.miRNAs are a small family of noncoding RNAs that play important roles in the development of human diseases by negatively regulating gene expression at either post-transcriptional or translational levels [3,4]. Over the last decade, many miRNAs have been showed in regulating diverse biological events such as cell proliferation, differentiation and apoptotic processes [5][6][7], which are important in the development of cancer. Accumulated evidence indicated that aberrant expression of miRNAs associates with various types of cancer. These dysregulated miRNAs function as either oncogenes or tumor suppressors in carcinogenesis and progression of cancers [8,9]. Thus, to explore the aberrant miRNAs expression in osteosarcoma might lead to the discovery of novel miRNAs biomarkers.In this study, we found that miR-20a was downregulated in osteosarcoma samples and osteosarcoma cell lines, and the ectopic expression of miR-20a reduced cell colony formation in vitro and tumor growth in vivo. Furthermore, bioinformatic prediction and experimental validation revealed that the function of miR-20a was probably exerted via targeting the TAK1 expression. To translate these findings, overexpression of miR-20a sensitizes the osteosarcoma cells to chemotherapeutic drugs. Collectively, our data identify the key role of miR-20a in osteosarcoma growth, indicating its potential application in cancer chemotherapy.

show abstract

A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep

Cited by 46 publications

References 144 publications

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

MicroRNA‑496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma

Cold Atmospheric Plasma in the Treatment of Osteosarcoma

MiRNA-20A Upregulates TAK1 and Increases Proliferation in Osteosarcoma Cells

Contact Info

Product

Resources

About